India Pharma Outlook Team | Tuesday, 26 August 2025
Eris Lifesciences Limited an Indian specialized manufacturer of branded formulations achieved that its Ahmedabad plant has been approved by ANVISA which is the national health authority of Brazil. This came off the back of an inspection by ANVISA that was conducted in May 2025 and means that Eris can enter Brazil as it is the largest pharma market in South America.
According to the firm, the approval from a stringent regulatory authority such as ANVISA is strong endorsement for Eris' GMP and quality systems. Earlier this year, the Ahmedabad facility has passed inspections by other international regulatory authorities.
Eris Lifesciences has established a strong position in the Indian pharma space with branded revenue exceeding ?3,000 crore per AWACS. With a diversified portfolio across specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women's Health, Oncology and Critical Care.
Eris Lifesciences offers a broad range of products including oral solids, liquids, softgels, ointments, sprays, sterile injectables and biologics for human use that it manufactures at 6 facilities certified globally.
Also Read: Healthium Medtech and C-CAMP Roll Out Medical Innovation Cohort in India
Eris has a significant domestic presence, with a marketing and distribution network consisting of approximately 5,000 stockists and more than 500,000 retail pharmacies across the country. Its contiunuously growing business model has led to revenue and operating profit increasing 2.6 times over five years, with FY25 revenue being reported at ?2,894 crore.
Aside from expanding its product pipeline, in the past three years, Eris has invested around ?4,000 crore to expand its presence across geographies, technologies, and therapeutic areas. With the recent ANVISA approval, Eris is now poised to further its international presence and gain access into the fast-growth Latin American pharmaceutical market.
